Adcoris

Adcoris is a China-based clinical-stage biopharmaceutical company developing next-generation antibody-drug conjugates and broader antibody conjugates (AXC) for oncology and autoimmune diseases. Its proprietary platform combines payload chemistry, linker technology, and multifunctional site-specific conjugation to generate homogeneous ADCs, including dual-payload and bispecific conjugates. The company has at least two clinical-stage programs, including ACR246, a 5T4-targeting ADC in Phase 1/2a for advanced solid tumors, and ZV0203/ADC2122, a pertuzumab-based HER2 ADC in Phase 1. Adcoris also maintains a broader preclinical pipeline spanning Nectin-4, TROP2, EGFR/c-Met, and undisclosed targets. In addition to internal programs, the company has partnered selected assets, including a collaboration with Lunan and a 2026 global licensing deal with K2 Therapeutics for ACR246.